Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 11/20 | 0.68 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.58 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.43 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6030912 | 0.85 | NR4A2 (0.50) | NR4A2CREBBPCYP2A6RAB9AALOX5 | |
| SCHEMBL5592328 | 0.84 | NR4A2 (0.49) | NR4A2CREBBPCYP2A6RAB9A | |
| SCHEMBL7552732 | 0.84 | GABRA1 (0.52) | NR4A2CYP2A6 | |
| SCHEMBL9937305 | 0.83 | NR4A2 (0.70) | NR4A2CREBBPRAB9AMAP2K1 | |
| SCHEMBL15348693 | 0.82 | PBRM1 (0.54) | NR4A2CREBBPCYP2A6 | |
| SCHEMBL2035795 | 0.81 | NR4A2 (0.68) | NR4A2CREBBPMAP2K1 | |
| SCHEMBL5329797 | 0.81 | NR4A2 (0.68) | NR4A2CREBBPRAB9A | |
| SCHEMBL9937058 | 0.81 | NR4A2 (1.00) | NR4A2CREBBPRAB9AMAP2K1 | |
| SCHEMBL26250363 | 0.81 | NR4A2 (0.68) | NR4A2CREBBPRAB9AMAP2K1 | |
| SCHEMBL2769281 | 0.80 | CYP2A6 (0.53) | NR4A2CYP2A6RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12144816-B2 | Substituted indole Mcl-1 inhibitors | VANDERBILT UNIVERSITY (US) | 2024-11-19 | — | — | US | disclosed |
| EP-4292662-A2 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | Vanderbilt University (US) | 2023-12-20 | — | — | EP | disclosed |
| US-20230330099-A1 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | VANDERBILT UNIVERSITY | 2023-10-19 | — | — | US | disclosed |
| EP-3423435-B1 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | UNIV VANDERBILT (US) | 2023-08-23 | — | — | EP | disclosed |
| US-11596639-B2 | Substituted indole Mcl-1 inhibitors | VANDERBILT UNIVERSITY (US) | 2023-03-07 | — | — | US | disclosed |
| US-20220324803-A1 | PROSTAGLANDIN E2 RECEPTOR 4 ANTAGONISTS AND USES THEREOF | TEON THERAPEUTICS INC (US) | 2022-10-13 | — | — | US | disclosed |
| CN-109153643-B | Substituted indole MCL-1 inhibitors | 范德比尔特大学 | 2022-06-21 | — | — | CN | disclosed |
| EP-3983412-A1 | PROSTAGLANDIN E2 RECEPTOR 4 ANTAGONISTS AND USES THEREOF | Teon Therapeutics, Inc. (US) | 2022-04-20 | — | — | EP | disclosed |
| CN-114206866-A | Prostaglandin E2Receptor 4 antagonists and uses thereof | 泰昂治疗公司 | 2022-03-18 | — | — | CN | disclosed |
| US-20210283138-A1 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | VANDERBILT UNIVERSITY | 2021-09-16 | — | — | US | disclosed |
| WO-2020251957-A1 | PROSTAGLANDIN E2 RECEPTOR 4 ANTAGONISTS AND USES THEREOF | TEON THERAPEUTICS, INC. (US) | 2020-12-17 | — | — | WO | disclosed |
| WO-2020251957-A1 | PROSTAGLANDIN E2 RECEPTOR 4 ANTAGONISTS AND USES THEREOF | TEON THERAPEUTICS, INC. (US) | 2020-12-17 | — | — | WO | disclosed |
| EP-3423435-A1 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | Vanderbilt University (US) | 2019-01-09 | — | — | EP | disclosed |
| EP-1852420-B1 | Indole compounds for treating respiratory disorders | ONO PHARMACEUTICAL CO (JP) | 2012-10-17 | — | — | EP | disclosed |
| US-7728023-B2 | Indole compound and use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2010-06-01 | — | — | US | disclosed |
| US-20080188532-A1 | Indole Compound and Use Thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-08-07 | — | — | US | disclosed |
| EP-1852420-A1 | INDOLE COMPOUND AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-11-07 | — | — | EP | disclosed |
| EP-1836174-A2 | ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | AMGEN INC. (US) | 2007-09-26 | — | — | EP | disclosed |
| WO-2006039718-A2 | ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | AMGEN INC (US) | 2006-04-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210283138-A1 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | MCL1, BCL2L1, BCL9 | NR4A2 2684/4885CREBBP 61/4885CYP2A6 4620/4885 |
| US-20220324803-A1 | PROSTAGLANDIN E2 RECEPTOR 4 ANTAGONISTS AND USES THEREOF | PTGER4, PTGER1, PTGER2 | NR4A2 104/4885CREBBP 271/4885CYP2A6 586/4885 |
| US-12144816-B2 | Substituted indole Mcl-1 inhibitors | MCL1, BCL2L1, BCL9 | NR4A2 2684/4885CREBBP 61/4885CYP2A6 4620/4885 |
| US-20230330099-A1 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | MCL1, BCL2L1, BCL9 | NR4A2 2684/4885CREBBP 61/4885CYP2A6 4620/4885 |
| US-11596639-B2 | Substituted indole Mcl-1 inhibitors | MCL1, BCL2L1, BCL9 | NR4A2 2684/4885CREBBP 61/4885CYP2A6 4620/4885 |
| US-20080188532-A1 | Indole Compound and Use Thereof | CYSLTR1, LTC4S, IDO1 | NR4A2 2894/4885CREBBP 3168/4885CYP2A6 885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.